Reform the medicines access and reimbursement landscape
Roche is dedicated to fostering collaboration to align policies with the goal of improving patient care and healthcare innovation. By engaging with policymakers, Roche uses its global expertise as a healthcare pioneer to inform health policies that support sustainable systems and ensure patient access to treatments. Our evidence-based advocacy underscores our commitment to global health, addressing key issues like securing investment to ensure access to medicines, providing patients more convenient and efficient treatment models, and planning for future-proofed health innovation strategies.
Increase the availability of innovative treatment models to relieve system capacity and give patients more choice
We are proud of Roche’s contributions to medical innovations that transform disease treatment. However, these medicines are only meaningful if accessible to those in need. It is our responsibility to ensure access to our treatments.
Improved treatment delivery models are essential for effective and efficient patient care. Roche believes innovative methods, like
Partner with the government to develop future proofed health innovation strategies and frameworks
Detecting signs of illness and diagnosing disease as early as possible is crucial if we’re to improve health outcomes for New Zealanders. In New Zealand, we react to a diagnosis rather than plan for it - to do that requires a systems-change level of thinking. We want to partner with the government to ensure that affordable, sustainable, accurate, and early diagnosis is available for all New Zealanders.
Our positions
●
●
●
Media releases
You can find our media releases
Status of our medicines in New Zealand
You can find the current Pharmac funding status of our medicines on
Corporate engagement
We work closely with a range of corporate organisations to develop meaningful relationships across the healthcare industry and business. We are proud to be members of:
●
●
●
●
●
● Aotearoa Genomic Health Alliance
See information on our Transfer of Value reporting